HBV Disease Progression
AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD
- Details
- Category: Fibrosis & Cirrhosis
- Published on Wednesday, 25 November 2015 00:00
- Written by Liz Highleyman
Drinking coffee was associated with lower liver stiffness -- a non-invasive measure used to estimate liver fibrosis -- in people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease (NAFLD), researchers reported at the 2015 AASLD Liver Meeting last week in San Francisco. The study also showed a trend toward less liver fat build-up in people with NAFLD.
Antiviral Treatment for Hepatitis B Improves Liver Function after Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Thursday, 09 July 2015 00:00
- Written by Liz Highleyman
Early treatment with antiviral therapy can restore liver function and increase survival in chronic hepatitis B patients with decompensated cirrhosis who might otherwise need a liver transplant, according to a Korean study published in the June 2015 issue of Hepatology.
EASL 2015: HBV Patients on Long-term Entecavir or Tenofovir Have Low Mortality, HCC Still a Risk
- Details
- Category: HBV Disease Progression
- Published on Wednesday, 27 May 2015 00:00
- Written by Liz Highleyman
More than 95% of people with chronic hepatitis B were still alive after 5 years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread), and most deaths were due to non-liver-related causes, but hepatocellular carcinoma was still a major factor affecting mortality, researchers reported presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna.
ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 02 June 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor nivolumab (Opdivo) was a star of the show at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago, with study results showing that the drug demonstrated anti-tumor activity against hepatocellular carcinoma in a Phase 1/2 study, along with further Phase 3 evidence of its effectiveness against lung cancer and melanoma.
EASL 2015: Prenylation Inhibitor Lonafarnib Lowers Hepatitis Delta Viral Load During Therapy
- Details
- Category: Hepatitis Delta (HDV)
- Published on Tuesday, 12 May 2015 00:00
- Written by Liz Highleyman
Lonafarnib, a farnesyl transferase inhibitor that interferes with viral assembly, reduced hepatitis delta virus (HDV) levels by more than 3 log in a Phase 2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last month in Vienna. Combining lonafarnib with pegylated interferon for 8 weeks led to significantly greater HDV RNA declines than lonafarnib alone, but boosting with ritonavir achieved an even greater effect with an all-oral regimen. HDV viral load rose again after stopping therapy, however, and researchers are now evaluating longer treatment durations.
More Articles...
- Everolimus Did Not Improve Survival for Advanced Liver Cancer Patients
- EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- Increased Distance Reduces Likelihood of Liver Transplant
Web Design and Development by